Magnetic Amine-Functionalized UiO-66 for Oxaliplatin Delivery to Colon Cancer Cells: In Vitro Studies

Hashemzadeh, Alireza; Amerizadeh, Forouzan; Asgharzadeh, Fereshteh; Drummen, Gregor P. C.; Hassanian, Seyed Mahdi; Landarani, Mohammad; Avan, Amir; Sabouri, Zahra; Darroudi, Majid

doi:10.1007/s10876-021-02158-6

Cited by 16 publications

(11 citation statements)

References 66 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…After seeding cells (5 × 10 6 ) in 96-well plates, they were grown for 24 and 72 h. In the next step, cells were treated with 10 µL concentrations of Cisplatin (1–1,500 µg), Ti 3 C 2 @FA@Cisplatin (1–1,500 µg), and Ti 3 C 2 -Fe 3 O 4 @SiO 2 -FA-Cisplatin (1–1,500 µg) in the total volume of 200 μL cells per well. As previously described, the plates were then processed ( Hashemzadeh et al, 2022 ).…”

Section: Methodsmentioning

confidence: 99%

See 1 more Smart Citation

Two-dimensional-Ti3C2 magnetic nanocomposite for targeted cancer chemotherapy

Darroudi

Nazari

Karimzadeh

et al. 2023

Front. Bioeng. Biotechnol.

Self Cite

View full text Add to dashboard Cite

Introduction: Cervical cancer is the leading cause of cancer-related death in women, so novel therapeutic approaches are needed to improve the effectiveness of current therapies or extend their activity. In recent decades, graphene analogs, such as Mxene, an emerging class of two-dimensional (2D) graphene analogs, have been drawing considerable attention based on their intrinsic physicochemical properties and performance as potential candidates for tumor therapy, particularly for therapeutic purposes. Here we explored the targeted drug delivery in cervical cancer in in vivo model. Mxene-based nanocarriers are not able to be precisely controlled in cancer treatment.Method: To solve this problem, the titanium carbide-magnetic core-shell nanocarrier (Ti3C2-Fe3O4@SiO2-FA) is also developed to provide synergetic anticancer with magnetic controlling ability along with pH-responsive drug release. A xenograft model of the cervix was used to investigate the effects of Cisplatin alone, or in combination with Ti3C2@FA and Ti3C2@ Fe3O4@SiO2-FA, on tumor growth following histological staining for evaluation of necrosis.Result and Discussion: A significant tumor-growth suppression effect is shown when the Ti3C2-Fe3O4@SiO2-FA nanocarrier is magnetically controlled Cisplatin drug release. It reveals a synergistic therapeutic efficacy used in conjunction with pharmaceuticals (p < .001). According to the in vivo study, the Ti3C2@FA@Cisplatin nanocomposite exhibits less tumor growth than the drug alone or Ti3C2@FA@Cisplatin via increasing necrosis effect (p < .001). Through this study, Mxene nanosheets are expanded for biomedical applications, not only through the fabrication of biocompatible magnetic Mxene nanocomposite but also through the development of functionalization strategies that enable the magnetic Ti3C2 nanocomposite to load high levels of Cisplatin for cervical cancer treatment (242.5%). Hence, Ti3C2-Fe3O4@SiO2-FA nanocarriers would be promising candidates to improve cancer treatment efficiency.

show abstract

Section: Methodsmentioning

confidence: 99%

“…Images of spheroid sizes were analyzed with ImageJ ver. 1.8.0–112 (National Institutes of Health, Bethesda, MD, United States) ( Hashemzadeh et al, 2022 ).…”

Section: Methodsmentioning

confidence: 99%

Two-dimensional-Ti3C2 magnetic nanocomposite for targeted cancer chemotherapy

Darroudi

Nazari

Karimzadeh

et al. 2023

Front. Bioeng. Biotechnol.

Self Cite

View full text Add to dashboard Cite

show abstract

“…Using 3‐(4,5‐dimethylthiazol‐2‐yl)‐2,5‐diphenyltetrazolium bromide (MTT) assays, cisplatin, Fe 3 O 4 , and Fe 3 O 4 @SiO 2 @N‐Chit‐FA‐ cis were tested for their growth inhibitory properties 24 hours and 72 hours after treatment 64 . For this test, 5 × 10 6 TC1 cells were seeded in 96‐well plates and grown for 24 hours and 72 hours.…”

Section: Methodsmentioning

confidence: 99%

Fabrication of magnetic nanocomposite as responsive drug delivery vehicle for cervical cancer therapy

Darroudi

Nazari

Karimzadeh

et al. 2023

Applied Organom Chemis

Self Cite

View full text Add to dashboard Cite

The development of carriers for drug delivery faces significant challenges from a therapeutic perspective. The present study presents an innovative nanocarrier based on combination of functionalized magnetic nanocomposite nano‐chitosan and cisplatin. Hydrophobic drugs such as cisplatin could be delivered using magnetic nanoparticles modified with biocompatible copolymers. This study aimed to determine the antitumor effects of free cisplatin enhancement in cervical cancer cells using cisplatin‐encapsulated Fe3O4@SiO2@N‐Chit‐FA. An additional layer of nanochitosan was coated on top of the magnetic nanocomposite to increase its stability in aqueous solutions. Biocompatibility and cytotoxicity of Fe3O4@SiO2@N‐Chit‐FA‐cis complex were evaluated against the cervical cancer animal model in C57BL6 mice. An external magnetic field was used to test the in‐vivo uptake and distribution of Fe3O4@SiO2 @N‐Chit‐FA‐cis in tumor cells. The results showed that the released drug would induce its effects on a specific target area when an external magnetic field was applied, and Fe3O4@SiO2@N‐Chit‐FA‐cis can suppress tumor growth more than cisplatin alone via induction of tumor necrosis. Overall, Fe3O4@SiO2@N‐Chit‐FA nanocomposites hold great potential for use in targeted nanomedicine to deliver bio‐functional molecules.

show abstract

“…Similar to other reported nanoparticles, this study exerted the results of the MTT assay to examine the cytotoxicity impacts of ZnO-Gd-OXA NPs@polymer shell on colorectal cancer cells (Figure 9A). [88,89] Various concentrations of ZnO-Gd-OXA NPs@polymer shell (1-5 ppm) were applied to the CT-26 colorectal cancer cells for 24 h to explore the viability of cells in the presence of this nanomedicine. The results indicated the successful eradication of CT-26 cancer cells by the nano-drug with the IC50 value of 1.9 ppm.…”

Section: Zno-gd Containing Oxaliplatin Inhibits Cell Viabilitymentioning

confidence: 99%

The advance anticancer role of polymeric core‐shell ZnO nanoparticles containing oxaliplatin in colorectal cancer

Alavi

Maghami

Pakdel

et al. 2023

J Biochem & Molecular Tox

Self Cite

View full text Add to dashboard Cite

We evaluated the activity of core‐shell ZnO nanoparticles (ZnO‐NPs@polymer shell) containing Oxaliplatin via polymerization through in vitro studies and in vivo mouse models of colorectal cancer. ZnO NPs were synthesized in situ when the polymerization step was completed by co‐precipitation. Gadolinium coordinated‐ZnONPs@polymer shell (ZnO‐Gd NPs@polymer shell) was synthesized by exploiting Gd's oxophilicity (III). The biophysical properties of the NPs were studied using powder X‐ray diffraction (PXRD), Fourier transforms infrared spectroscopy, Ultraviolet‐visible spectroscopy (UV‐Vis), field emission electron microscopy (FESEM), transmission electron microscopy (TEM), atomic force microscopy, dynamic light scattering, and z‐potential. (3‐(4,5‐Dimethylthiazol‐2‐yl)−2,5‐diphenyltetrazolium bromide) (MTT) was used to determine the antiproliferative activity of ZnO‐Gd‐OXA. Moreover, a xenograft mouse model of colon cancer was exerted to survey its antitumor activity and effect on tumor growth. In the following, the model was also evaluated by histological staining (H‐E; Hematoxylin & Eosin and trichrome staining) and gene expression analyses through the application of RT‐PCR/ELISA, which included biochemical evaluation (MDA, thiols, SOD, CAT). The formation of ZnO NPs, which contained a crystallite size of 16.8 nm, was confirmed by the outcomes of the PXRD analysis. The Plate‐like morphology and presence of Pt were obtained in EDX outcomes. TEM analysis displayed the attained ZnO NPs in a spherical shape and a diameter of 33 ± 8.5 nm, while the hydrodynamic sizes indicated that the particles were highly aggregated. The biological results demonstrated that ZnO‐Gd‐OXA inhibited tumor growth by inducing reactive oxygen species and inhibiting fibrosis, warranting further research on this novel colorectal cancer treatment agent.

show abstract

Magnetic Amine-Functionalized UiO-66 for Oxaliplatin Delivery to Colon Cancer Cells: In Vitro Studies

Cited by 16 publications

References 66 publications

Two-dimensional-Ti3C2 magnetic nanocomposite for targeted cancer chemotherapy

Two-dimensional-Ti3C2 magnetic nanocomposite for targeted cancer chemotherapy

Fabrication of magnetic nanocomposite as responsive drug delivery vehicle for cervical cancer therapy

The advance anticancer role of polymeric core‐shell ZnO nanoparticles containing oxaliplatin in colorectal cancer

Contact Info

Product

Resources

About